Liang R H, Chiu E K, Chan T K, Todd D, Loke S L
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
Hematol Oncol. 1990 May-Jun;8(3):147-54. doi: 10.1002/hon.2900080306.
The treatment result of 271 cases of advanced stage intermediate grade lymphoma were reviewed. Ninety-four patients received CHOP chemotherapy, 45 BACOP and 17 m-BACOD. The clinical characteristics of the three groups of patients were comparable. Patients receiving CHOP had a complete response (CR) rate of 60 per cent, the disease-free survival of CR patients was 31 per cent at 5 years. The overall survival following CHOP chemotherapy was 38 per cent at 5 years. The use of the BACOP or m-BACOD regime did not appear to improve significantly the prognosis of these patients. Clinical staging, B symptoms, age and serum lactate dehydrogenase level were the most important independent prognostic factors.
回顾了271例晚期中度恶性淋巴瘤患者的治疗结果。94例患者接受CHOP化疗，45例接受BACOP化疗，17例接受m-BACOD化疗。三组患者的临床特征具有可比性。接受CHOP化疗的患者完全缓解（CR）率为60%，CR患者的无病生存率在5年时为31%。CHOP化疗后的总生存率在5年时为38%。使用BACOP或m-BACOD方案似乎并未显著改善这些患者的预后。临床分期、B症状、年龄和血清乳酸脱氢酶水平是最重要的独立预后因素。
